Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Harvard Business School
Merck
Colorcon
McKinsey

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,691,506

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 8,691,506
Title:Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds
Abstract: The present invention relates to a method for providing a gene expression profile being predictive for the specific response of an individual tumor to a pharmaceutically effective compound, the use thereof, a microarray wherein the nucleotide sequences attached to the substrate consist of nucleotide sequences corresponding to the predictive genes of said gene expression profile, and a diagnostic kit containing said microarray.
Inventor(s): Bausch; Niko (Freiburg, DE), Fiebig; Heinz-Herbert (Freiburg, DE), Korrat; Andre (Freiburg, DE), Maurer; Martina (Freiburg, DE), Metz; Thomas (Glottertal, DE), Schuler; Julia (Freiburg, DE)
Assignee: Oncotest GmbH (Freiburg, DE)
Application Number:11/911,222
Patent Claims:1. A diagnostic kit containing a microarray, the microarray comprising the nucleotide sequences of SEQ ID NO.:1 to 118 attached to a substrate, the nucleotide sequences corresponding to the predictive genes of a gene expression profile obtained by a method for providing a gene expression profile being predictive for the specific response of an individual tumor to Avastin, the method comprising the steps of: (a) xenotransplanting human tumor material of at least five different tumors into at least one suitable test animal, (b) determining gene expression profiles of the resulting tumor xenografts, (c) treating said at least one test animal with Avastin, (d) evaluating responsiveness of the tumor xenografts to Avastin, (e) identifying the gene expression profile of each of the tested tumor xenografts, and (f) determining the predictive genes in the gene expression profiles by comparing the gene expression profiles of responsive tumors, no-change tumors and progressive tumors, wherein step (f) comprises the steps of (i) dividing the complete set of gene expression profiles of the tumor xenografts into sub-sets, each of the sub-sets missing one of said gene expression profiles, (ii) determining the predictive genes in each sub-set, and (iii) obtaining the gene expression profile being predictive for the specific response of an individual tumor to Avastin by setting up the intersection of the predictive genes of all sub-sets.

2. The kit according to claim 1, wherein in step (f) a tumor xenograft is considered to be responsive when its T/C (therapy/control) value is less than 25%.

3. The kit according to claim 1, wherein in step (f) a tumor xenograft is considered to be no-change when its T/C (therapy/control) value is ranges from 25% to 42%.

4. The kit according to claim 1, wherein in step (f) a tumor xenograft is considered to be progressive when its T/C (therapy/control) value is more than 42%.

5. The kit according to claim 1, wherein in step (ii) an expression profile of 300 genes is determined for each sub-set.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
05008088Apr 13, 2005
PCT Information
PCT FiledApril 13, 2006PCT Application Number:PCT/EP2006/003421
PCT Publication Date:October 19, 2006PCT Publication Number:WO2006/108659

Details for Patent 8,691,506

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Oncotest GmbH (Freiburg, DE) 2025-04-13 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Oncotest GmbH (Freiburg, DE) 2025-04-13 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Johnson and Johnson
Moodys
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.